2. Каратеев Д.Е., Лучихина Е.Л., Тогизбаев Г. Современные принципы ведения больных ранним артритом. Русский медицинский журнал. 2008;24:1610.

3. Grigor C., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–69. Doi: 10.1016/S0140-6736(04)16676-2.

4. Conigliaro P., et al. Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev. 2019;18(7):706–13. Doi: 10.1016/j.autrev.2019.05.007.

5. Genovese M.C., et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020. Doi: 10.1016/s2665-9913(20)30032-1.

6. Szekanecz Z., et al. Eight pillars of oncorheumatology: crossroads between malignancies and musculoskeletal diseases. Autoimmun Rev. 2020;19(11):102658. Doi: 10.1016/j.autrev.2020.102658

7. Figus F.A., et al. Rheumatoid arthritis: extra- articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776. Doi: 10.1016/j.autrev.2021.102776.

8. Hadwen B., et al. Risk factors for hypertension in rheumatoid arthritis patients-a systematic review. Autoimmun Rev. 2021;20(4):102786. Doi: 10.1016/j.autrev.2021.102786.

9. Berger M., et al. Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases. Autoimmun Rev. 2021;20(9):102891. Doi: 10.1016/j. autrev.2021.102891.

10. Atzeni F., et al. Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? Autoimmun Rev. 2019;18(12):102401. Doi: 10.1016/j.autrev.2019.102401.

11. Pawar A., et al. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020.

12. van Vollenhoven R. Treat-to-target in rheumatoid arthritis – are we there yet? Nat Rev Rheumatol. 2019;15(3):180–86. Doi: 10.1038/s41584- 019-0170-5.

13. Ebrahimian S., et al. Can treating rheumatoid arthritis with disease-modifying anti-rheumatic drugs at the window of opportunity with tight control strategy lead to long-term remission and medications free remission in real-world clinical practice? A cohort study. Clin Rheumatol. 2021;40(11):4485–91. Doi: 10.1007/s10067-021-05831-3.

14. Heuvelmans J., et al. Effectiveness and tolerability of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis. Rheumatology (Oxford). 2021;61(1):331–36. Doi: 10.1093/ rheumatology/keab313.